GenNext & SCIEX to Co-Market an Advanced High Order Structure Analysis (HOS) Workflow for Biopharmaceutical Research
Together, the companies will spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics.
Half Moon Bay, CA and Framingham, MA – September 14, 2023 – GenNext Technologies, Inc., provider of novel instrumentation, software, and services for structural biology research, revealed their agreement to co-market a robust workflow for Hydroxyl Radical Protein Footprinting (HRPF) studies with SCIEX, a global leader in life science analytical technologies. The announcement was made at the 2023 California Separation Science Society combined Mass Spectrometry and Higher Order Structure (CASSS MS/HOS) meetings.
The agreement leverages each company’s products to create a novel structural biology workflow to advance higher order structure analysis of biotherapeutics. GenNext’s Flash Oxidation (Fox®) Protein Footprinting System performs covalent labeling of biotherapeutic products. Mass spectrometry analysis is then performed on the ZenoTOF 7600 system from SCIEX, followed by high resolution data analysis to be done by GenNext’s FoxWare® Data Processing Software.
GenNext’s Fox System easily performs higher order structure studies for biotherapeutic discovery and development that previously required complicated, expensive, and lasers or beamline sources. Pairing the FOX system to the ZenoTOF 7600 system enables the acquisition of high-resolution mass spectrometry data. The powerful MS/MS sensitivity and enhanced ion fragmentation technology of the ZenoTOF 7600 system allows for localization of challenging PTMs and more comprehensive understanding of protein structure.
Data generated from the workflow collaboration will be showcased during the CASSS MS meeting at the poster presentation “Improving TNFα’s Epitope Identification with Residue Level Hydroxyl Radical Protein Footprinting using the ZenoTOF 7600 system,” presented by Emily Chea, of GenNext Technologies.
“We are proud to co-market with SCIEX, a top-tier innovator of high-resolution MS equipment,” said Scot Weinberger, CEO of GenNext Technologies. “The combined power of both companies’ products will help improve therapeutic efficacy and safety, accelerate biotherapeutic development.”
“The ZenoTOF 7600 system is a strong fit with the GenNext HOS system,” states Jose Castro-Perez, Senior Director Global Market Development at SCIEX. “Novel fragmentation with electron activate dissociation (EAD) technology on the system adds another dimension for structural characterization, providing information with the speed and accuracy needed to confidently accelerate biopharmaceutical and biosimilar development.”
This optimized GenNext/SCIEX workflow will help make the study of protein HOS more accessible, impactful, and transformative for biopharmaceutical researchers.
About GenNext Technologies
Located in the San Francisco Bay Area, GenNext Technologies, Inc., is a growth-stage company that provides instrumentation, software, and services to pharmaceutical researchers investigating biopharmaceutical structure, interactions, folding, aggregation, formulation, and delivery. Our powerful, compact, and cost-effective platform enables researchers to conduct reproducible Higher Order Structure experiments quickly, easily, and safely. We help our customers accelerate biopharmaceutical development, while improving therapeutic efficacy and safety. Ultimately, our mission is to enable structural biology researchers to discover and develop drug therapies that improve human health.
For more information, please visit www.gnxtech.com and follow us on Linkedin.
Contact
Scot R. Weinberger
Founder and CEO
[email protected]
650-726-1060
About SCIEX
SCIEX delivers solutions for the precision detection and quantitation of molecules, empowering our customers to protect and advance the wellness and safety of all. We have been at the forefront of the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.
Today, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers can quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.
That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.
For more information, visit sciex.com.
Let’s connect: Twitter, LinkedIn, Facebook and Instagram.
Advances in human wellness depend on the power of precise science.
Contact Information
Lulu VanZandt
Senior Manager, Brand, Public Relations and Social Media
[email protected]
M: +1 (508) 782-9484
The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.
Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).
© 2023 DH Tech. Dev. Pte. Ltd. MKT-29275-A.